Poxel SA
7PO
Company Profile
Business description
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.
Contact
259/261 Avenue Jean Jaures
Immeuble le Sunway
Lyon69007
FRAT: +33 437372010
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
6
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,757.90 | 13.20 | -0.15% |
| CAC 40 | 7,656.12 | 27.61 | -0.36% |
| DAX 40 | 23,317.81 | 116.84 | -0.50% |
| Dow JONES (US) | 42,171.66 | 44.14 | -0.10% |
| FTSE 100 | 8,843.47 | 9.44 | 0.11% |
| HKSE | 23,710.69 | 269.61 | -1.12% |
| NASDAQ | 19,546.27 | 25.18 | 0.13% |
| Nikkei 225 | 38,885.15 | 348.41 | 0.90% |
| NZX 50 Index | 12,627.32 | 12.03 | -0.10% |
| S&P 500 | 5,980.87 | 1.85 | -0.03% |
| S&P/ASX 200 | 8,531.20 | 10.10 | -0.12% |
| SSE Composite Index | 3,388.81 | 1.40 | 0.04% |